Picture this… Earlier this morning, you walked into the first board meeting feeling confident.
Six months ago, your team worked hard to close this deal. Your standard diligence process was thorough with plenty of scrutiny over the company financials and tech stack, and their leadership team looked solid. The growth model made sense. Revenue was trending up. Pipeline looked healthy.
But now, sitting across from the CEO, something feels off. He looks nervous.
The meeting kicks off with a pipeline review and the numbers look fine, but deals are taking twice as long to close as projected.
Marketing is busy – campaigns running, events booked, content shipping – but sales keeps saying the leads aren’t converting.
Churn is creeping up, but customer success blames it on “fit issues” that no one can define.
The CEO keeps saying the team is executing. And they are. Hard.
But growth isn’t compounding the way the model assumed it would.
You leave that meeting with a question you wish you’d asked differently six months earlier:
Not “Can this company grow?” but “How exactly does this company grow, and what could throw a wrench in their growth engine?”
The best investors don’t wait until the first board meeting to ask how growth actually works.
They diagnose it during diligence, before capital is deployed and expectations are set.
Seems obvious, right? GTM structure literally determines whether growth is repeatable, scalable, and resilient. Yet it’s still rarely validated with the same rigor as financials during diligence — even when growth is central to the thesis.
The best PE and VC firms are changing that. They’re asking sharper questions earlier that are designed to surface the risks data rooms can’t show.
Why These Questions Matter
Standard diligence answers what’s happening. These questions uncover why, and whether the GTM motion is actually a system or just a collection of workarounds held together by institutional knowledge.
Because if it’s the latter, it won’t survive new ownership, higher growth expectations, or the departure of a few key people.
These questions surface misalignment between executives, expose gaps between strategy and execution, and reveal whether the conditions that produced past performance will hold under pressure.
Weak answers might not kill deals. But they tell you exactly where post-close friction will surface, and what needs to be fixed before you scale spend.
The 9 GTM Questions Smart Investors Ask
1. How do you know your ICP is right?
Every company can describe their ideal customer. Few can prove they’ve validated it.
The question isn’t “Who’s your ICP?” It’s: What data supports that definition? How was it tested? Does the executive team share the same definition, or does it shift depending on who you ask?
What weak answers reveal:
ICP is assumed, not validated. Marketing, sales, and customer success are likely optimizing for different buyer types, which can generate pipeline volume but weak close rates and high churn.
2. How does your GTM motion align with how your customers actually buy?
This tests whether the company understands buyer behavior or is just executing a playbook that worked somewhere else.
Do customers want to self-serve, or do they need hand-holding? Are deals committee-driven or individual? Does the sales cycle match how prospects actually evaluate and decide?
What weak answers reveal:
The GTM motion was designed around internal assumptions, not external buyer reality. If there’s friction baked into the process, scaling will amplify it.
3. Where in your funnel is friction highest, and what’s causing it?
Every funnel has friction. The question is whether leadership can name it and explain the root cause.
Are leads stalling at demo? Is pricing causing hesitation? Are deals getting stuck in legal? Is onboarding creating early churn?
What weak answers reveal:
No one is diagnosing the funnel. They’re just pushing harder on tactics. Without clarity on the root-cause, spend increases but conversion doesn’t.
4. What are the top 3 reasons you lose deals, and do you analyze wins and losses the same way?
This is one of the most revealing questions in diligence.
Strong companies don’t just track why they lose, they analyze wins and losses through the same process. They know whether they’re losing on price, product fit, trust, or competitive positioning. And they can tell you whether their wins follow a repeatable pattern or depend on unique circumstances.
Weak companies guess. Or worse, they blame external factors for losses (“budget got pulled,” “they went with the incumbent”) while attributing wins to execution without examining why their process worked in those cases.
What weak answers reveal:
The company doesn’t have a real win/loss analysis process. They can’t distinguish between repeatable success and lucky breaks. If they don’t know why they win and lose through the same analytical lens, they can’t reliably scale.
5. How repeatable is your sales process across reps, regions, or deal types?
Repeatability is the difference between a GTM system and a team of hero sellers.
Can new reps ramp quickly, or does success depend on tenure and tribal knowledge? Does the process work across segments, or does it break down when you move upmarket or expand geographically?
What weak answers reveal:
Growth is dependent on specific people, not scalable systems. Turnover will hurt. Geographic expansion will be slow. Headcount won’t drive linear growth.
6. How does marketing hand off to sales, and where does that handoff break?
This question exposes whether marketing and sales are aligned or operating in silos.
Is there a formalized handoff process, or is it informal? Do both teams agree on what qualifies as a sales-ready lead? Where do leads get lost or deprioritized?
What weak answers reveal:
Marketing and sales don’t share definitions, incentives, or accountability. Pipeline coverage may look strong, but much of it is unqualified or stuck in limbo.
7. What’s the one growth lever you haven’t pulled yet, and why not?
This tests strategic maturity and self-awareness.
Strong teams know what’s left in the playbook. They can articulate why certain levers haven’t been pulled (resource constraints, sequencing, market readiness) and what would change if capital were available.
Weak teams say, “We just need more budget” without clarity on where to deploy it.
What weak answers reveal:
The company is guessing. There’s no strategic roadmap, just tactical hope that more spend will drive more growth.
8. If you doubled your growth target for next year, what needs to be true to hit it?
This tests whether leadership thinks structurally or just does spreadsheet math.
Strong answers go beyond the numbers. They identify the conditions that need to exist: “We’d need to expand into a new geography, which requires local market expertise and regulatory knowledge we don’t have yet. Or we’d need to successfully launch Product X, which depends on dev capacity we’re still building.”
Weak answers stay in the spreadsheet: “We’d need 4x pipeline and higher close rates.” (True, but doesn’t explain how or what changes to make that possible.)
What weak answers reveal:
Leadership hasn’t thought through the structural dependencies. They can forecast numbers but can’t articulate what organizational, market, or strategic shifts are required to achieve them.
9. What’s your plan for the first 90 days post-investment?
This reveals whether the team knows how to translate capital into momentum (or if they’re just hoping more resources will solve everything).
Strong answers are specific:
- Month 1: hire VP of Sales and finalize enterprise pricing
- Month 2: launch outbound motion with 2 SDRs
- Month 3: pilot new onboarding process to reduce time-to-value.
Weak answers are vague: “We’ll scale up marketing and hire more reps.” (No sequencing, no prioritization, no understanding of dependencies.)
What weak answers reveal:
The team hasn’t thought through execution. They assume capital solves problems, but they don’t have a clear plan for how to deploy it or what order things need to happen.
What These Questions Actually Reveal
These questions aren’t designed to produce right or wrong answers. They’re designed to surface qualitative signals that data rooms can’t show:
- Misalignment between executives — If the CEO, CMO, and CRO give different answers, strategy isn’t shared.
- Inconsistent narratives — If positioning changes depending on who’s talking, it’s not actually positioning.
- Lack of evidence — If core assumptions aren’t backed by data, they’re guesses.
- Poor understanding of constraints — If leadership can’t name bottlenecks, they won’t know where to invest.
Strong answers don’t guarantee success. But weak answers tell you exactly where post-close friction will surface. And whether the team has the self-awareness to diagnose and fix it.
What to Do If You Don’t Like the Answers
You have three options:
1. Dig deeper with your ops team.
If the answers are unclear but not disqualifying, your portfolio support team can work with leadership to build clarity post-close. This works, but it’s slower and riskier than diagnosing pre-close.
2. Build GTM clarity into your first 90 days.
Make structural GTM alignment a Day 1 priority. Don’t wait for issues to surface. Diagnose immediately and course-correct before capital scales the wrong things.
3. Bring in independent GTM diagnosis before you deploy capital.
This is why we built Fathom360, to pressure-test GTM structure with the same rigor investors apply to financials or product/tech. We don’t validate the CEO’s narrative. We diagnose the system. And we do it in a diligence-compatible timeframe, so you have clarity before expectations are locked in and momentum is committed.
When firms get this right, the impact compounds: faster post-close ramps, better hiring decisions, fewer mid-flight corrections, and board conversations grounded in shared understanding instead of competing theories.
Growth Is Too Important to Assume
Smart investors don’t assume…they verify.
And in growth-stage investing, GTM isn’t just important…it’s foundational.
GTM diligence isn’t about slowing deals down. It’s about speeding up impact without the expensive missteps that come from scaling a system no one ever validated.
Before you close your next growth-dependent deal, ask these questions. Listen closely to the answers. And if clarity isn’t there, get it…before capital gets deployed.
Download the GTM Question Guide — a starting point for evaluating go-to-market structure during diligence.
These questions will surface risk. If you want to diagnose it before you deploy capital, let’s talk.
Fathom360 is a forensic-grade GTM diagnostic that gives investors the same level of structural clarity for go-to-market that they get for financials. We map dependencies, surface misalignment, and deliver a prioritized roadmap – all in a diligence-compatible timeframe.
You get clarity before the deal closes, not six months later in a stressful board meeting.
